demonstrated to be both efficacious and well-tolerated.

However, it is
necessary for the individual who has taken this dosage to wait and observe
whether there has been any hair growth or not. It is not advisable to escalate
the dosage in the absence of favorable outcomes. The topical formulation of
finasteride has been demonstrated to be less commonly associated with
adverse effects compared to the oral formulation, as evidenced by a study
reporting 30 to 50% fewer severe side effects [40].

References

38. Hirshburg, J.M., et al., Adverse effects and safety of 5-alpha reductase
inhibitors (finasteride, dutasteride): a systematic review. 2016. 9(7): p. 56.

39. Kang, D.W., et al., Pharmacokinetic-pharmacodynamic modeling

approach for dose prediction of the optimal long-acting injectable formulation
of finasteride. 2021. 601: p. 120527.

40. Todeschini, D., I.P. Martinez, and M.D. Duque. Topical finasteride dose
evaluation for treatment of androgenetic alopecia using computer simulations.
in Annales Pharmaceutiques Françaises. 2022. Elsevier.

(16): 01:51:00 Post-Finasteride Syndrome

The occurrence of Post-Finasteride Syndrome is attributed to the utilization of

finasteride. Finasteride has been recommended as a therapeutic agent for
managing prostate-related conditions, with a standard dosage of
approximately five milligrams per day. The dosage administered is
considerably high, and for a prolonged period, there was no discourse